uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Stathmin as a Marker for Malignancy in Pheochromocytomas
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Pharmacology. (Cancer Pharmacology and Informatics/Rolf Larsson)
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Show others and affiliations
2010 (English)In: Experimental and clinical endocrinology & diabetes, ISSN 0947-7349, E-ISSN 1439-3646, Vol. 118, no 1, 27-30 p.Article in journal (Refereed) Published
Abstract [en]

Pheochromocytomas of the adrenal medulla may be life-threatening catecholamine-producing tumors which are malignant in about 10% of cases. Differential diagnosis between malignant and benign tumors is dependent on the development of metastasis or extensive local invasion. A number of genetic aberrations have been described in pheochromocytomas, but no marker associated to malignancy has been reported. We applied an expression microarray containing 7770 cDNA clones and analysed the expression profiles in eleven tumors compared to normal adrenal medulla. Stathmin (STMN1, Op18) was most conspiciously overexpressed among the differentially expressed genes. RT-PCR analysis further confirmed mRNA overexpression, 6 to 8-fold for benign and malignant tumors, and 16-fold for metastases. Stathmin protein overexpression was observed by immunohistochemistry, and distinct differential protein expression between benign and malignant/metastasis specimens was confirmed by Western blot analysis. The results introduce stathmin as a possible diagnostic marker for malignant pheochromocytomas, and further evaluations are warranted.

Place, publisher, year, edition, pages
2010. Vol. 118, no 1, 27-30 p.
Keyword [en]
Benign, Malignant, Microarray, Op18, Pheochromocytoma, Stathmin, STMN1
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-113090DOI: 10.1055/s-0029-1202789ISI: 000274245700006PubMedID: 19449284OAI: oai:DiVA.org:uu-113090DiVA: diva2:289652
Available from: 2010-01-25 Created: 2010-01-25 Last updated: 2017-12-12

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Björklund, PeymanFryknäs, MårtenIsaksson, AndersÅkerström, GöranHellman, PerWestin, Gunnar

Search in DiVA

By author/editor
Björklund, PeymanFryknäs, MårtenIsaksson, AndersÅkerström, GöranHellman, PerWestin, Gunnar
By organisation
Department of Surgical SciencesClinical PharmacologyDepartment of Medical Sciences
In the same journal
Experimental and clinical endocrinology & diabetes
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 490 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf